[go: up one dir, main page]

MA30056B1 - Formulation de precurseur de medicament contre le hcv - Google Patents

Formulation de precurseur de medicament contre le hcv

Info

Publication number
MA30056B1
MA30056B1 MA31038A MA31038A MA30056B1 MA 30056 B1 MA30056 B1 MA 30056B1 MA 31038 A MA31038 A MA 31038A MA 31038 A MA31038 A MA 31038A MA 30056 B1 MA30056 B1 MA 30056B1
Authority
MA
Morocco
Prior art keywords
formulation
against hcv
drug precursor
precursor against
butyryloxy
Prior art date
Application number
MA31038A
Other languages
English (en)
Inventor
Hashim A Ahmed
Thomas Vernon Alfredson
Kondamraj Birudaraj
Michael Thomas Brandl
Wantanee Phuapradit
Navnit Hargovindas Shah
Dimitrios Stefanidis
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA30056B1 publication Critical patent/MA30056B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

FORMULATION DE PRECURSEUR DE MEDICAMENT CONTRE LE HCV La présente invention concerne une composition pharmaceutique comprenant une suspension solide préparée par extrusion en fusion à chaud de chlorhydrate d'isobutyrate de (2R,3S,4R,5R)-5-(4-amino-2-oxo-2H-pyrimidin-l-yl)-2-azido-3,4-bis-iso-butyryloxy-tétrahydrofuran-2-ylméthyle (I) et d'un copolymère séquence de polyéthylène glycol (PEG)/polypropylène glycol (PPG).
MA31038A 2005-12-14 2008-06-16 Formulation de precurseur de medicament contre le hcv MA30056B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75014605P 2005-12-14 2005-12-14
US83059406P 2006-07-12 2006-07-12

Publications (1)

Publication Number Publication Date
MA30056B1 true MA30056B1 (fr) 2008-12-01

Family

ID=37806115

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31038A MA30056B1 (fr) 2005-12-14 2008-06-16 Formulation de precurseur de medicament contre le hcv

Country Status (21)

Country Link
US (1) US7795237B2 (fr)
EP (1) EP1962808B1 (fr)
JP (1) JP5649783B2 (fr)
KR (1) KR20080089344A (fr)
AR (1) AR058313A1 (fr)
AT (1) ATE482690T1 (fr)
AU (1) AU2006326130B2 (fr)
BR (1) BRPI0619890A2 (fr)
CA (1) CA2631498A1 (fr)
CR (1) CR10026A (fr)
DE (1) DE602006017257D1 (fr)
DK (1) DK1962808T3 (fr)
EC (1) ECSP088528A (fr)
IL (1) IL191791A (fr)
MA (1) MA30056B1 (fr)
NO (1) NO20082563L (fr)
PL (1) PL1962808T3 (fr)
PT (1) PT1962808E (fr)
RU (1) RU2435592C2 (fr)
TW (1) TWI382840B (fr)
WO (1) WO2007068615A2 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8957034B2 (en) * 2004-01-28 2015-02-17 Johns Hopkins University Drugs and gene carrier particles that rapidly move through mucous barriers
RU2454220C2 (ru) 2006-08-16 2012-06-27 Новартис Аг Способ получения твердых дисперсий высококристаллических терапевтических соединений
WO2008030557A2 (fr) * 2006-09-08 2008-03-13 Johns Hopkins University Compositions et méthodes destinées à améliorer le transport à travers le mucus
ES2377760T3 (es) 2007-03-29 2012-03-30 F. Hoffmann-La Roche Ag Composición farmacéutica y proceso
SI2389164T1 (sl) * 2009-01-21 2014-12-31 F. Hoffmann-La Roche Ag Farmacevtski sestavki, obsegajoäśi predzdravilo inhibitorja hcv polimeraze
AR075180A1 (es) * 2009-01-29 2011-03-16 Novartis Ag Formulaciones orales solidas de una pirido-pirimidinona
GB0909680D0 (en) 2009-06-05 2009-07-22 Euro Celtique Sa Dosage form
PL2528930T3 (pl) * 2010-01-28 2014-03-31 Riboscience Llc 4`-azydonukleozydy jako związki przeciw hcv
MX344846B (es) 2010-05-10 2017-01-10 Euro-Celtique S A * Combinacion de granulos cargados activos con activos adicionales.
US9993433B2 (en) 2010-05-10 2018-06-12 Euro-Celtique S.A. Manufacturing of active-free granules and tablets comprising the same
ES2408343B2 (es) 2010-05-10 2014-07-17 Euro-Celtique, Sa Composiciones farmacéuticas que comprenden hidromorfona y naloxona
CA3054532C (fr) * 2010-11-05 2022-07-12 The Johns Hopkins University Compositions et procedes visant a une reduction de la mucoadherence
EP2455068A1 (fr) * 2010-11-09 2012-05-23 F. Hoffmann-La Roche AG Composition pharmaceutique pour le traitement d'infections par VHC
WO2012062691A1 (fr) * 2010-11-09 2012-05-18 F. Hoffmann-La Roche Ag Compositions pharmaceutiques pour le traitement des infections par le virus de l'hépatite c
JP5917964B2 (ja) * 2012-03-19 2016-05-18 富士ゼロックス株式会社 錠剤、錠剤の製造方法、錠剤管理装置、錠剤照合装置及びプログラム
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
AU2013256130B2 (en) * 2012-05-03 2017-12-21 Alcon Inc. Pharmaceutical nanoparticles showing improved mucosal transport
AU2013256064B2 (en) 2012-05-03 2018-01-04 Alcon Inc. Pharmaceutical nanoparticles showing improved mucosal transport
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
AU2014216178B2 (en) 2013-02-15 2018-06-28 KALA BIO, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
CN105189462B (zh) 2013-02-20 2017-11-10 卡拉制药公司 治疗性化合物和其用途
AU2014342042B2 (en) 2013-11-01 2017-08-17 KALA BIO, Inc. Crystalline forms of therapeutic compounds and uses thereof
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP3068397A1 (fr) 2013-11-13 2016-09-21 Euro-Celtique S.A. Hydromorphone et naloxone utilisées pour le traitement de la douleur et du syndrome de dysfonctionnement intestinal dû aux opioïdes
EP3509422A4 (fr) 2016-09-08 2020-05-20 Kala Pharmaceuticals, Inc. Formes cristallines de composés thérapeutiques et leurs utilisations
CN109688818A (zh) 2016-09-08 2019-04-26 卡拉制药公司 治疗化合物的晶型及其用途
CA3036340A1 (fr) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Formes cristallines de composes therapeutiques et leurs utilisations
EP3381479A1 (fr) * 2017-03-29 2018-10-03 ARTOSS GmbH Composition de support pour matériau de substitution osseuse

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2260319B (en) * 1991-10-07 1995-12-06 Norsk Hydro As Acyl derivatives of nucleosides and nucleoside analogues having anti-viral activity
DK1014941T3 (da) * 1996-06-26 2009-07-27 Univ Texas Ekstruderbar farmaceutisk hot-melt-formulering
AU754370B2 (en) * 1997-06-03 2002-11-14 Itochu Techo-Chemical Inc. Natural antitumor or antiviral substances and use of the same
JP2001520984A (ja) * 1997-10-27 2001-11-06 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 水難溶性薬剤の固態溶剤及び固体分散体
RU2187509C1 (ru) * 2001-03-26 2002-08-20 Закрытое акционерное общество "Производственно-коммерческая Ассоциация АЗТ" Производные 5'-h-фосфоната 3'-азидо-3'-дезокситимидина и фармацевтические композиции на их основе
EP1390063B1 (fr) * 2001-05-03 2004-11-17 F. Hoffmann-La Roche Ag Forme dosifiee pharmaceutique de mesylate de nelfinavir amorphe
DE10162593A1 (de) * 2001-12-19 2003-07-03 Menarini Ricerche Spa Stabilisierte topische Brivudin-Formulierungen
DE10208344A1 (de) * 2002-02-27 2003-09-04 Roehm Gmbh Schmelzextrusion von Wirkstoffsalzen
TWI332507B (en) * 2002-11-19 2010-11-01 Hoffmann La Roche Antiviral nucleoside derivatives
US20050044529A1 (en) * 2003-08-20 2005-02-24 Microsoft Corporation Task library of task data for a plurality of components on a computer system
US20050048112A1 (en) * 2003-08-28 2005-03-03 Jorg Breitenbach Solid pharmaceutical dosage form

Also Published As

Publication number Publication date
EP1962808A2 (fr) 2008-09-03
AR058313A1 (es) 2008-01-30
PL1962808T3 (pl) 2011-03-31
IL191791A0 (en) 2008-12-29
RU2435592C2 (ru) 2011-12-10
PT1962808E (pt) 2010-10-29
ATE482690T1 (de) 2010-10-15
US7795237B2 (en) 2010-09-14
NO20082563L (no) 2008-07-03
TW200803873A (en) 2008-01-16
RU2008128361A (ru) 2010-01-20
WO2007068615A2 (fr) 2007-06-21
ECSP088528A (es) 2008-07-30
AU2006326130A1 (en) 2007-06-21
JP5649783B2 (ja) 2015-01-07
CA2631498A1 (fr) 2007-06-21
TWI382840B (zh) 2013-01-21
WO2007068615A3 (fr) 2007-09-07
EP1962808B1 (fr) 2010-09-29
US20070202175A1 (en) 2007-08-30
CR10026A (es) 2008-07-29
DK1962808T3 (da) 2010-11-08
JP2009519289A (ja) 2009-05-14
BRPI0619890A2 (pt) 2011-10-25
KR20080089344A (ko) 2008-10-06
IL191791A (en) 2011-06-30
DE602006017257D1 (de) 2010-11-11
AU2006326130B2 (en) 2011-09-22

Similar Documents

Publication Publication Date Title
MA30056B1 (fr) Formulation de precurseur de medicament contre le hcv
EA201270738A1 (ru) Модуляторы фармакокинетических свойств лекарственных средств
BR0003364A (pt) Composições farmacêuticas
ATE469136T1 (de) Inhibitoren von 11-beta- hydroxysteroiddehydrogenase typ 1
ATE519486T1 (de) Pharmazeutische zusammensetzung mit einem monoamin-neurotransmitter-wiederaufnahmehemmer und einem acetylcholinesterase-hemmer
CY1112963T1 (el) Σταθερες φαρμακευτικες συνθεσεις περιεχουσες 7-υποκατεστημενα-3,5-διυδροξυεπτανοϊκα οξεα ή 7-υποκατεστημενα-3,5-διυδροξυεπτενοϊκα οξεα
DE60138222D1 (de) Modulierung von il-2 und il-15 vermittelten t zellantworten
BR0209489A (pt) Composições farmacêuticas
WO2005082414A3 (fr) Médicaments associés
WO2002060385A3 (fr) Formulation pharmaceutique
BRPI0615860B8 (pt) composição farmacêutica de liberação prolongada monolítica sólida
BR0107564A (pt) Composição de gliburida
ATE555777T1 (de) Pharmazeutische zusammensetzung
MXPA05007609A (es) Antagonista de un receptor sensible al calcio.
EA200901393A1 (ru) Фармацевтическая композиция, содержащая гестагены и/или эстрогены и 5 метил-(6s)-тетрагидрофолат
MXPA06000791A (es) Formulaciones farmaceuticas.
WO2004058721A3 (fr) Modulateurs a petites molecules de l&#39;activite du facteur de croissance d&#39;hepatocyte (facteur de dispersion)
AU2363902A (en) Crystalline forms of fluvastatin sodium
BR9811557A (pt) Derivados do 2-)4-aril ou heteroaril-piperazin-1-ilmetil)-1h-indol
WO2005075471A3 (fr) Composes thiazole utilises en tant qu&#39;inhibiteurs de la 11-beta-hydroxysteroide deshydrogenase de type 1
WO2005118579A3 (fr) Composes chimiques
ATE301463T1 (de) Pharmazeutische zusammensetzungen enthaltend 17alpha-furanylester von 17beta-carbothioat androstanderivaten und einen muskarinrezeptorantagonist
BRPI0808377B8 (pt) composto, composição e uso de um composto
ATE432700T1 (de) Indol-4 -sulfonamid-derivate, ihre herstellung und verwendung als 5-ht-6 modulatoren
PE20090066A1 (es) Composiciones farmaceuticas en base a granulos de un derivado de azidocitidina y un copolimero de bloques y procedimiento de preparacion